| 引用本文:黄迎春，马丽荣，刘盼功，张明霞.冠心病PCI术后应用参七汤对冠脉再狭窄的临床预防干预效果观察[J].世界中医药,2016,(06):. |
|
| 冠心病PCI术后应用参七汤对冠脉再狭窄的临床预防干预效果观察 |
| Clinical Prevention and Intervention Effect of Shenqi Decoction on Coronary Restenosis of Coronary Heart Disease After PCI |
| 投稿时间：2016-01-13 |
| DOI：10.3969/j.issn.1673-7202.2016.06.017 |
| 中文关键词: 冠心病 PCI 参七汤 冠脉再狭窄 |
| English Keywords:Coronary heart disease PCI Shenqi Decoction Coronary Restenosis |
| 基金项目:卫生部医药卫生科技发展项目（编号：W2013GJ09） |
|
| 摘要点击次数: 957 |
| 全文下载次数: 932 |
| 中文摘要: |
| 目的：观察冠心病PCI术后患者应用参七汤对冠脉再狭窄的临床预防干预效果。方法：我院收治的218例冠心病患者按照随机数字表法分为研究组和对照组，每组109人。对照组给予西医常规治疗。研究组在对照组方案上加用参七汤。对比2组治疗前后中医证候积分、炎性反应指标的变化，对比冠脉再狭窄发生率。结果：研究组在服药3个月及服药6个月时的气虚证候积分及血瘀证候积分下降幅度显著优于同期的对照组（P<0.05）。研究组服药3个月及服药6个月后的超敏C-反应蛋白、活化T淋巴细胞、可溶性白细胞介素-2受体水平均显著优于同期对照组（P<0.05）。研究组再狭窄发生率为17.43%，显著低于对照组的34.86%（P<0.05）。结论：冠心病PCI术后应用参七汤可显著优化患者的中医证候，遏制患者体内的慢性炎性反应状态，提升免疫水平，降低冠脉再狭窄风险。 |
| English Summary: |
| To observe the clinical prevention and intervention effect of Shenqi decoction on coronary restenosis of patients with coronary heart disease after PCI.Methods:A total of 218 patients with coronary heart disease treated in this hospital were divided into the research group and control one according to the random number table,with 109 cases in each group.Patients in the control group were given the routine western medicine therapy; while patients in the research group were given the treatment of Shenqi decoction in addition to the routine western medicine therapy.The changes of TCM syndrome scores and changes of inflammatory markers before and after the treatment and incidence of coronary restenosis were compared between two groups.Results:The magnitude of decrease in qi deficiency symptom score and blood stasis syndrome score of patients at 3 months and 6 months after taking the medicine in the research group were significantly better than those in the control group (P<0.05).The levels of high-sensitivity C-reactive protein,activated T lymphocytes and soluble interleukin-2 receptor at 3 months and 6 months after the treatment the treatment in the research group were significantly better than those in the control group (P<0.05).The incidence of restenosis for patients in the research group was 17.43%,which was significantly lower than 34.86% of control group (P<0.05).Conclusion:The application of Shenqi decoction in the coronary heart disease after PCI can significantly improve the TCM syndrome scores of patients,inhibit the chronic inflammatory state,enhance the immunity levels and reduce the risk of coronary restenosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
